Zai Lab (ZLAB) Asset Utilization Ratio (2021 - 2026)

Zai Lab (ZLAB) posted Asset Utilization Ratio of 0.4 for Q1 2026, up 1.25% sequentially from 0.39 in Q4 2025, and up 12.7% YoY from 0.35 in Q1 2025.

Analysis

Zai Lab (ZLAB) Asset Utilization Ratio (2021 - 2026) Analysis & Trends

Zai Lab has reported Asset Utilization Ratio for 6 years, with the latest figure at 0.4 in Q1 2026.

Quarterly Asset Utilization Ratio rose 12.7% year-over-year to 0.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.4 (up 12.7% YoY) and the FY2025 annual result came in at 0.39, up 8.68% from the prior year.
Asset Utilization Ratio advanced to 0.4 in Q1 2026 per ZLAB's latest filing, from 0.39 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.4 in Q1 2026 and troughed at 0.11 in Q1 2022.
A 5-year average of 0.28 and a median of 0.29 in 2024 frame the typical range for Asset Utilization Ratio.
The sharpest annual moves came in 2022 and 2025: Asset Utilization Ratio soared 127.27% in 2022, then gained 5.42% in 2025.
Over 5 years, Asset Utilization Ratio stood at 0.17 in 2022, then jumped by 50.19% to 0.26 in 2023, then jumped by 43.31% to 0.37 in 2024, then advanced by 7.4% to 0.39 in 2025, then gained by 1.25% to 0.4 in 2026.
According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.4, 0.39, and 0.38 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.38
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.20
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.69
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	0.90
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.13
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.54
10	Zai Lab	2.94 Bn	2.23 Bn	58.15 Mn	0.41

Historic Data

Download Data